– Oral semaglutide at 25 mg daily achieved a substantial mean weight loss of 13.6% over 64 weeks in adults with overweight or obesity.
– This oral formulation offers a non-injectable alternative to existing injectable semaglutide therapies.
– Significant improvements in physical function and quality of life indices were observed.
– Gastrointestinal side effects were common but manageable, highlighting the need for clinical monitoring.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
